Are people really falling ill from touching fentanyl? In most cases, scientists say no

Many of the recent reports of police and other people overdosing from incidental contact with fentanyl are probably false alarms, experts say.

Police officers hospitalized after incidental exposure to fentanyl. A Florida child fatally overdosed. In communities around the country, such headlines are stoking fears that a momentary brush with a tiny amount of fentanyl powder could prove fatal.

The synthetic opioid, blamed for increasing numbers of overdose deaths across the U.S., is 50 to 100 times more potent than morphine. But experts consulted by STAT said many of the reported incidents appear to be false alarms that run counter to scientific fact and exaggerate the risks.

The American College of Medical Toxicology recently issued a position  concluding that, based on what’s been publicly released, none of the recent incidents involving first responders is consistent with opioid toxicity. The doctors, who reviewed a handful of cases, said they are not challenging the truthfulness of the officers involved. Rather, they are questioning whether their reports are verified cases of poisonings that carry the hallmarks of

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readScience
Merck And Sanofi Buy Smaller Cancer Drug Firms At Big Premiums, Fueling Investor Excitement
Merger Monday: Merck announces it will purchase ArQule, a developer of pills aimed at treating multiple cancers, and Sanofi says it will buy Synthorx, a San Diego firm working on…
STAT3 min readSociety
Opinion: Cutting 700,000 Americans From SNAP Will Increase Health Costs
The mission of the United States Department of Agriculture, which oversees SNAP, is to "do right and feed everyone." The Trump administration's rule to cut people from SNAP does wrong.
STAT4 min read
Detailed Data On Biogen’s Resurrected Alzheimer’s Drug Raise More Questions Than Answers
SAN DIEGO — Biogen on Thursday presented detailed data making a case for its resurrected Alzheimer’s drug, arguing that its mixed study results can be explained away by differences in whether patients got the highest dose of the medicine. But the new